GlassScriptPhysician profile
Philippe W Petrus
NPI 1639398035
$5,802.60
in general payments reported to CMS, 2019-2025
19 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,406 · 2022: $797 · 2023: $1,315 · 2024: $1,055 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,510 · Education: $89.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,510.18 |
| Education | $89.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,183.88 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $925.13 | 2021-2025 | Ingrezza |
| Abbvie INC. | $754.69 | 2021-2025 | |
| Alkermes, INC. | $626.66 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $494.80 | 2021-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $376.29 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $223.16 | 2023 | Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $210.08 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Acadia Pharmaceuticals INC | $205.89 | 2023-2024 | Nuplazid |
| Lundbeck LLC | $201.00 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $182.28 | 2024-2025 | Cobenfy |
| Sage Therapeutics, LLC | $113.11 | 2025 | Zurzuvae |
| Takeda Pharmaceuticals U.S.A., INC. | $107.74 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $65.23 | 2025 | Fanapt |
| Corium, LLC | $52.39 | 2022-2024 | Azstarys |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $24.90 | 2023 | Igalmi |
| Ironshore Pharmaceuticals INC. | $20.02 | 2024 | |
| Tris Pharma INC | $19.90 | 2023 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $15.45 | 2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philippe Petrus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.